Magnesium For Prevention and Treatment of Coronary Artery Disease by Jeffrey Dach MD

A shocking number of Americans suffer from coronary artery disease. Millions are now taking statin drugs, blood pressure pills, water pills and other medications, yet the epidemic continues. What if the answer lies in a simple, inexpensive mineral that most doctors overlook? Magnesium.

In my office, I see patients every day with coronary artery disease, high blood pressure, and cardiac arrythmias. Many have low magnesium levels on testing the RBC Magnesium. When we correct the magnesium deficiency with diet and supplementation, the results are often dramatic: better energy, fewer symptoms, and improved lab markers. Why does magnesium work so well? It is not one single effect. It works through multiple mechanisms that directly address the root causes of atherosclerosis and coronary artery disease.

Important Point: Magnesium is not a drug. It is a natural mineral cofactor for hundreds of enzymes in the body.

Header Image: Crystal structure of Mg2SiO4 (olivine, Pnma) projected onto the (a, b) plane. Green: magnesium atoms, yellow: silicon atoms, blue: oxygen atoms. Author Perditax, Public Domain, Wikimedia commons.

Magnesium Deficiency is widespread because modern diets are low in magnesium-rich foods, and many common medications deplete it further.

Here are the key reasons magnesium is so effective:

1. Anti-Inflammatory Properties

In 2006, Dr. Stephan J Ott demonstrated that coronary artery plaque is fundamentally a polymicrobial biofilm demonstrated by multiple independent labs using 16s ribosome genetic sequencing of atherosclerotic plaque specimens.  The plaque in your arteries is not just a passive buildup of cholesterol. It is an active infectious process driven by the microbes originating in the gut and pharynx causing immune reaction and calcification. Infection is one of the strongest triggers in the human body for an inflammatory reaction, thus causing soft tissue calcification in response to intense inflammation. (1)

Inflammatory Pathways Activated

Low magnesium activates inflammatory pathways such as NF-κB and the NLRP3 inflammasome, raising cytokines like CRP, IL-6, and TNF-α. This promotes plaque formation, endothelial activation, and monocyte recruitment. Magnesium supplementation reliably lowers these inflammatory markers. Multiple randomized controlled trials and meta-analyses confirm this benefit, especially in patients who are deficient.

In 2022, Dr. Nicola Veronese did a meta-analysis of 17 randomized trials and found significant reductions in CRP (C-reactive protein, a non-specific inflammatory marker, and other inflammatory markers with magnesium supplementation. The magnesium calms down the inflammatory and immune-driven progression of atherosclerotic plaque. (2)

2. Metabolism and Mitochondrial Function

Magnesium is the single most important nutrient for our mitochondria, the power plants inside every cell. Magnesium is required for ATP synthesis, the Tricarboxylic Acid (TCA) cycle, and electron transport chain enzymes. Without adequate magnesium, mitochondria cannot produce energy efficiently. This leads to increased oxidative stress, calcium overload, and impaired energy metabolism in heart muscle and vascular cells.

Magnesium deficient mitochondria means more inflammation, and inhibition of the reverse cholesterol transport mechanism. Restoring magnesium improves ATP production and cardiac diastolic function, which is especially helpful in heart failure with preserved ejection fraction.

In 2020, Drs. Man Liu and Samuel Dudley reviewed the many mechanisms of magnesiums benefits and stated that magnesium(Mg) supplementation improves mitochondrial function and cardiac diastolic performance in diabetics, The authors write:

In this review, we discuss the possible mechanisms by which Mg deficiency plays detrimental roles in cardiovascular diseases and review the results of clinical trials of Mg supplementation for heart failure, arrhythmias and other cardiovascular diseases…Mg supplementation has shown significant therapeutic effects in HF [heart failure] and CVD [cardio-vascular disease] …. It has also been shown to improve arrhythmias including torsades de pointes (TdP, polymorphic ventricular tachycardia with marked QT prolongation on the electrocardiogram), atrial fibrillation (AF) , ventricular arrhythmias (VA), and arrhythmias in acute myocardial infarction (MI).

3. Antioxidant Properties

Arterial wall breaks are induced by sheer stress at arterial bifurcations, allowing entrance of poly-microbial infection and oxidized LDL particles which incite inflammation, soft tissue calcification and progression of atherosclerotic plaque. Microbial infection of the arterosclerotic plaque, inflammation and calcification and oxidative stress are the initiating events of atherosclerosis.

Magnesium deficiency increases reactive oxygen species (ROS) from mitochondria and depletes antioxidant defenses such as superoxide dismutase and glutathione. At the cellular level, magnesium stabilizes cell membranes, supports enzymatic antioxidants, and reduces lipid peroxidation. It directly counters oxidative damage to cells.The comprehensive review by Drs. Man Liu and Samuel Dudley details these antioxidant mechanisms and their importance in cardiovascular protection.

4. Nitric Oxide Synthesis and Endothelial Function

The endothelium is the inner lining of your arteries, and this is the weak link in vascular health. Endothelial dysfunction means the arteries become stiff, constricted, and subject to damage. Enter Nitric Oxide, the protector of endothelial function. Magnesium is essential for endothelial nitric oxide synthase (eNOS) activity and nitric oxide (NO) production, which keeps vessels dilated and healthy.

Magnesium deficiency with low magnesium RBC levels will reduce nitric oxide production (NO), increase adhesion molecules, and promote vasoconstriction and thrombosis. Magnesium supplementation improves flow-mediated dilation, the standard clinical test of endothelial function, and exercise tolerance in patients with coronary artery disease.

Shecter Oral Magnesium Improves Endothelial Function

A landmark randomized trial in 2000 by Dr. Michael Shechter in Circulation showed that oral magnesium therapy significantly improved endothelial function in patients with coronary artery disease. This is one of the most cited studies in the field. (4)

5. Reduction in Atherosclerotic Plaque

Clinical Evidence from a 2019 Randomized Trial

Further strong support comes from a well-designed 2019 randomized, double-blind, placebo-controlled trial by Dr. Hamid Reza Talari. In this study, diabetic patients on hemodialysis received a modest dose of only 150 mg of magnesium oxide, one of the cheapest and poorly absorbed forms of magnesium. The effect of magnesium supplementation was studied with ultrasound imaging of the carotid arteries. Despite the conservative dose and lower absorption rate, the results were impressive and wide-ranging:

Vascular Health:

In the 2019 study by Dr. Hamid Reza Talari’s using ultrasound imaging to measure carotid intima thickness, there was significant reduction in mean carotid intima-media thickness (CIMT), meaning less atherosclerotic plaque buildup in the carotid arteries. The carotid arteries are the two large arteries (right and left) in the neck which supply blood flow to the brain.

Glycemic Control and Insulin Sensitivity:

Dr. Talari’s study also showed magnesium decreases fasting insulin,  lowers HbA1c, lowers high-sensitivity CRP (hs-CRP), increases total antioxidant capacity (TAC) and lowers cholesterol.

Dr. Talari’s is particularly convincing because it was conducted in a very high-risk population, in diabetic patients with advanced kidney disease, yet still produced meaningful improvements across vascular and metabolic parameters, and inflammatory markers with a simple, inexpensive form of magnesium (magnesium oxide). (5)

Talari, Hamid Reza, et al. “Effects of Magnesium Supplementation on Carotid Intima–Media Thickness and Metabolic Profiles in Diabetic Haemodialysis Patients: A Randomised, Double-Blind, Placebo-Controlled Trial.” British Journal of Nutrition, vol. 121, no. 7, 2019, pp. 809–817.

https://doi.org/10.1017/S0007114519000163
(Full text: https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effects-of-magnesium-supplementation-on-carotid-intimamedia-thickness-and-metabolic-profiles-in-diabetic-haemodialysis-patients-a-randomised-doubleblind-placebocontrolled-trial/8B90A9D2ABD0F23DB232935B7113CCE4)

Direct Imaging Evidence in Human Clinical Studies: Magnesium Supplementation Slows and Reverses Atherosclerotic Plaque Progression

The 2019 study by Dr. Talari using carotid ultrasound is impressive. There are many other human clinical trials using a variety of imaging techniques, ultrasound for carotid intima-media thickness, CT scanning for coronary artery calcium scores, and standard vascular imaging for arterial calcifications, have shown that magnesium supplementation can actually slow, stop, or even reverse the progression of atherosclerotic plaque in the arteries. These studies use objective medical imaging techniques to demonstrate magnesium is able to reduce atherosclerotic plaque. In my experience, correcting magnesium deficiency is very beneficial for the patient concerned about coronary artery disease risk. Here are six additional key human studies confirming the benefits of magnesium:

1. Carotid Intima-Media Thickness (Ultrasound) – Hemodialysis Patients (Turgut 2008)

In this 2008 double-blind randomized controlled trial by Dr. Faruk Turgut, patients with chronic kidney disease on hemodialysis received oral magnesium supplementation. Ultrasound measurements of the carotid arteries showed a significant reduction in intima-media thickness, a direct marker of atherosclerotic plaque burden, compared with baseline. In contrast, the placebo group showed progression of plaque thickness during the same period. This study provides clear visual proof that magnesium can help shrink existing plaque in very high-risk dialysis patients. (6)

Turgut, Faruk, et al. “Magnesium Supplementation Helps to Improve Carotid Intima Media Thickness in Patients on Hemodialysis.” International Urology and Nephrology, vol. 40, no. 4, 2008, pp. 1075–82, https://doi.org/10.1007/s11255-008-9410-3.
PubMed: https://pubmed.ncbi.nlm.nih.gov/18568412/

2. Carotid Intima-Media Thickness and Flow-Mediated Dilatation (Ultrasound) – Hemodialysis Patients (Mortazavi 2013)

In this 2013 double-blind, randomized, placebo-controlled trial by Dr. Mohammad  Mortazavi involved 54 patients with kidney failure on hemodialysis. Those given oral magnesium oxide showed a significant decrease in carotid intima-media thickness (plaque marker), while the placebo group experienced an increase. The plaque-reducing effect remained statistically significant even after adjusting for other risk factors. The study also measured flow-mediated dilatation to assess endothelial function, reinforcing magnesium’s protective role in the artery wall. (7)

Mortazavi, Mohammad, et al. “Effect of Magnesium Supplementation on Carotid Intima-Media Thickness and Flow-Mediated Dilatation among Hemodialysis Patients: A Double-Blind, Randomized, Placebo-Controlled Trial.” European Neurology, vol. 69, no. 5, 2013, pp. 309–16, https://doi.org/10.1159/000346427.
PubMed: https://pubmed.ncbi.nlm.nih.gov/23548855/

3. Subclinical Atherosclerosis (CIMT and Endothelial Markers) – Hypertensive Women (Cunha 2017)

In this 2017 randomized controlled trial by Dr. Ana Cunha, women with hypertension who were already taking thiazide diuretics (a “water pill” class of blood-pressure medication known to deplete magnesium) received oral magnesium supplementation. The magnesium group showed improved endothelial function and a clear slowing of subclinical atherosclerosis progression as measured by carotid intima-media thickness and related vascular imaging markers. Many of my hypertensive patients are on similar medications, making this study especially relevant. (8)

Cunha, Ana Rosa, et al. “Oral Magnesium Supplementation Improves Endothelial Function and Attenuates Subclinical Atherosclerosis in Thiazide-Treated Hypertensive Women.” Journal of Hypertension, vol. 35, no. 1, 2017, pp. 89–97, https://doi.org/10.1097/HJH.0000000000001129.
PubMed: https://pubmed.ncbi.nlm.nih.gov/27759579/

4. Coronary Artery Calcium Score (CT Imaging) – Hemodialysis Patients (Spiegel 2009 Pilot Study)

In this 2009 open-label pilot study by Dr. David Spiegel used magnesium carbonate as a phosphate binder (providing supplemental magnesium) for hemodialysis patients with kidney failure. Serial CT scans measured coronary artery calcium (CAC) scores over 18 months. The magnesium group showed only about an 8% increase in calcification, dramatically less than the typical 50% or greater progression seen with standard calcium-based binders. This is one of the most striking demonstrations that magnesium can markedly slow dangerous coronary plaque calcification.

In this small 2009 open-label pilot study by Dr. David M. Spiegel and colleagues, seven chronic hemodialysis patients with baseline coronary artery calcium (CAC) scores >30 received magnesium carbonate (combined with some calcium carbonate) as their primary phosphate binder for 18 months. Serial electron-beam CT (EBCT) scans showed only minimal, non-statistically significant progression in CAC scores, specifically, median percent changes of approximately 8% at 6 months, 3.9% at 12 months, and 8% at 18 months. This was dramatically slower than the typical annual CAC progression rates of 25–75% (or greater) reported in the literature for similar hemodialysis patients using calcium-based phosphate binders (the historical/comparator rates the study referenced). The authors concluded that magnesium “may have a favorable effect on CAC.” (9)

Spiegel, David. M., and B. Farmer. “Long-Term Effects of Magnesium Carbonate on Coronary Artery Calcification and Bone Mineral Density in Hemodialysis Patients: A Pilot Study.” Hemodialysis International, vol. 13, no. 3, 2009, pp. 453–59, https://doi.org/10.1111/j.1542-4758.2009.00364.x.
PubMed: https://pubmed.ncbi.nlm.nih.gov/19469885/

5. Coronary Artery Calcification (CT Imaging) – Predialysis CKD Patients (Sakaguchi 2019 RCT)

In this 2019 randomized controlled trial by Dr. Yusuke Sakaguchi,  patients with stage 3–4 chronic kidney disease received oral magnesium oxide (or a comparator carbon adsorbent). Serial CT calcium scoring showed that the magnesium group had significantly slower progression of coronary artery calcification, while the control group did not. This provides strong randomized evidence of the benefit of magnesium in a non-dialysis chronic kidney disease (CKD) population. (10)

Sakaguchi, Yusuke, et al. “A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD.” Journal of the American Society of Nephrology, vol. 30, no. 6, 2019, pp. 1073–85, https://doi.org/10.1681/ASN.2018111150.
Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC6551769/

6. Arterial Calcifications (Vascular Imaging) – Hemodialysis Patients (Tzanakis 2014 Pilot Study)

In this 2014 pilot study by Dr. Ioannis P. Tzanakis, hemodialysis patients with kidney failure were given magnesium supplementation showing a clear slowing of progression of arterial calcification. Standard vascular imaging techniques documented slower advancement of calcified plaque burden compared with controls. Once again, magnesium demonstrated a direct benefit with slowed progression of atherosclerotic plaque. (11)

Tzanakis, Ioannis P., et al. “Magnesium Retards the Progress of the Arterial Calcifications in Hemodialysis Patients: A Pilot Study.” International Urology and Nephrology, vol. 46, no. 12, 2014, pp. 2199–205, https://doi.org/10.1007/s11255-014-0791-1.
PubMed: https://pubmed.ncbi.nlm.nih.gov/25118610/

Important Point: All of these studies used real-world patients with advanced disease (hemodialysis, CKD, hypertension) and relatively modest doses of magnesium, often inexpensive forms such as magnesium oxide or citrate. Yet the imaging showed measurable plaque improvement or slowed progression. This is the kind of evidence that should make every cardiologist and nephrologist take notice.

These imaging studies, combined with the mechanisms we discussed earlier (anti-inflammatory, antioxidant, endothelial, mitochondrial, and lipid effects), explain why correcting magnesium deficiency produces such consistent clinical benefits. Feel free to share this with your doctor. Knowledge is power.

Preclinical Evidence: Animal Studies Confirm Magnesium Reduces Atherosclerotic Plaque

Animal models provide clear mechanistic proof that magnesium supplementation directly reduces atherosclerotic plaque formation, carotid intima-media thickness (CIMT), and vascular calcification across multiple species and disease models.

Here are six well-designed studies:

Ouchi et al. 1990 (Cholesterol-Fed Rabbits): Dietary magnesium supplementation significantly suppressed the development of atherosclerotic lesions in the aorta. Male New Zealand White rabbits (n = 31) were placed on five kinds of diets: regular, 1% cholesterol, and 1% cholesterol diets supplemented with either 300, 600, or 900 mg (as Mg) of Mg sulfate. The regular and 1% cholesterol diets contained 400 mg of Mg per 100 g. Each rabbit received 100 g daily of the appropriate diet. Additional Mg was well tolerated and did not affect blood pressure or body weight. The rabbits were sacrificed after 10 weeks, and the oil red O-positive atherosclerotic area that covered the aortic intima and the cholesterol content of the aorta was measured. Additional Mg decreased both the area of the aortic lesions and the cholesterol content of the aortas in a dose-dependent manner. The 1% cholesterol diet significantly increased plasma cholesterol and triglyceride concentrations and decreased high density lipoprotein (HDL) cholesterol concentration…These results indicate that dietary Mg prevents the development of atherosclerosis in cholesterol-fed rabbits.
Ouchi, Y., et al. “Effect of Dietary Magnesium on Development of Atherosclerosis in Cholesterol-Fed Rabbits.” Arteriosclerosis, vol. 10, no. 5, 1990, pp. 732–737. https://doi.org/10.1161/01.ATV.10.5.732 (Full text: https://www.ahajournals.org/doi/10.1161/01.ATV.10.5.732)

Ravn et al. 2001 (ApoE-Deficient Mice): Oral magnesium supplementation on a low-fat diet significantly reduced atherosclerotic plaque area in the aortic root by 66% in female mice, (p<0.02). Mice fed magnesium in their drinking water also had lower cholesterol and triglyceride levels.

Ravn, Hanne B., et al. “Oral Magnesium Supplementation Induces Favorable Antiatherogenic Changes in ApoE-Deficient Mice.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 5, 2001, pp. 858–862. https://doi.org/10.1161/01.atv.21.5.858 (Full text: https://www.ahajournals.org/doi/10.1161/01.atv.21.5.858)

King et al. 2009 (Atherogenic Diet Rabbits): Higher dietary magnesium (+Mg group) significantly reduced aortic plaque formation and intimal thickness compared with magnesium-deficient animals. Aortas from Mg deficient rabbits had significantly more plaque, with an intima thickness 42% greater than controls. The authors write:

Our study demonstrates that inadequate intake of Mg results in a marked increase in atherosclerotic plaque development in rabbits fed a hypercholesterolemic diet. …Our findings support the epidemiological and in vivo observations that adequate Mg intake can help to decrease incidence of atherosclerotic disease and that assessment of adequate Mg status or dietary intake of Mg might be a good addition to therapy and prevention of CVD. Our findings suggest that serum Mg levels do not correlate with degree of atherosclerotic plaque development and that erythrocyte Mg [Magnesium RBC] levels might be of interest when assessing Mg status clinically.

King, Jennifer L., et al. “Inadequate Dietary Magnesium Intake Increases Atherosclerotic Plaque Development in Rabbits.” Nutrition Research, vol. 29, no. 5, 2009, pp. 343–349. https://doi.org/10.1016/j.nutres.2009.05.001 (Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC3277285/)

Kupetsky-Rincon et al. 2012 (Abcc6−/− Mice – Accelerated Atherosclerosis Model)
Magnesium supplementation slowed carotid intima-media thickness progression by nearly 50% (from 8.3 μm/month untreated to 4.5 μm/month treated).
Kupetsky-Rincon, Erine A., et al. “Magnesium Reduces Carotid Intima-Media Thickness in a Mouse Model of Pseudoxanthoma Elasticum: A Novel Treatment Biomarker.” Clinical and Translational Science, vol. 5, no. 3, 2012, pp. 259–264. https://doi.org/10.1111/j.1752-8062.2011.00390.x (Full text: https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1111/j.1752-8062.2011.00390.x)

López-Baltanás et al. 2023 (Rat Model of Metabolic Syndrome + Renal Failure)
Dietary magnesium supplementation reduced oxidative stress, inflammation, and vascular dysfunction, preventing progression of atherosclerosis-related pathology.
López-Baltanás, R., et al. “Dietary Mg Supplementation Decreases Oxidative Stress, Inflammation, and Vascular Dysfunction in an Experimental Model of Metabolic Syndrome with Renal Failure.” Antioxidants, vol. 12, no. 2, 2023, p. 283. https://doi.org/10.3390/antiox12020283 (Full text: https://www.mdpi.com/2076-3921/12/2/283)

Díaz-Tocados et al. 2017 (Uremic Rat Model): Magnesium supplementation prevented and reversed vascular calcification and atherosclerotic changes in a uremic rat model of chronic kidney disease.
Díaz-Tocados, J. M., et al. “Magnesium Supplementation Prevents Vascular Calcification in a Uremic Rat Model.” Nephrology Dialysis Transplantation, 2017 (widely cited in reviews). PubMed: https://pubmed.ncbi.nlm.nih.gov/28158710/ (Full text available via journal).

DiNicolantonio

A thorough review by DiNicolantonio and colleagues in Open Heart discusses these mechanisms in detail and notes magnesium’s role in preventing and treating cardiovascular disease.

Magnesium Useful for Cardiac Arrythmias/ Atrial Fibrillation/PVCs

A shocking number of Americans suffer from heart rhythm disorders every year. Symptoms such as palpitations and skipped beats may indicate premature ventricular contractions (PVCs), premature atrial contractions (PACs), and atrial fibrillation. This may cause patients to seek care at the emergency room. Cardiologists treat millions withbeta blockers, anti-arrhythmic drugs, or blood thinners, yet the arrythmias are still here and increasing. What if the answer lies in a simple, inexpensive mineral that most cardiologists overlook? Magnesium.

In my office, I see patients every day with irregular heartbeats, atrial fibrillation, and troublesome PVCs. Many have low magnesium levels when properly tested (RBC magnesium). When we correct the deficiency with diet and supplementation, the results are often dramatic: fewer palpitations, more stable rhythms, and patients who finally feel in control again. Why does magnesium work so well for heart rhythm disorders? It is not one single effect. It works through multiple mechanisms that directly stabilize the heart’s electrical system.

Important Point: Magnesium is not a drug. It is a natural mineral cofactor for hundreds of enzymes in the body, including those that control the heart’s electrical conduction. Deficiency is widespread because modern diets are low in magnesium-rich foods, and many common medications (diuretics, proton pump inhibitors, and some blood pressure drugs) deplete it further. Low magnesium is a hidden trigger for arrhythmias that most doctors never check.

Here are the key reasons magnesium is so effective for heart rhythm disorders:

1. Membrane Stabilization and Ion Channel Regulation

Magnesium acts as a natural calcium channel blocker and stabilizes cardiac cell membranes. It helps regulate potassium, sodium, and calcium movement across heart cells. Low magnesium leads to increased excitability, early after-depolarizations, and re-entrant circuits that trigger PVCs, PACs, and atrial fibrillation. Restoring magnesium calms this electrical instability.

2. Na/K ATPase Pump Function

Magnesium is an essential cofactor for the sodium-potassium ATPase pump that maintains the heart’s resting membrane potential. Without enough magnesium, the pump fails, potassium leaks out of cells, and arrhythmias become more likely. This is why low magnesium and low potassium often occur together and why fixing magnesium is crucial even when potassium levels look “normal.”

3. Anti-Inflammatory and Antioxidant Effects in the Heart

Chronic low-grade inflammation and oxidative stress damages the heart’s conduction system and promote atrial fibrillation. Magnesium reduces inflammation and oxidative damage, thus protecting the sensitive electrical pathways.

Clinical Evidence from Human Studies

The medical literature is clear. Magnesium supplementation (especially when deficiency is present) reduces the incidence of serious arrhythmias in multiple settings.

Post-Acute Coronary Syndrome Arrhythmias (Salaminia 2018 Meta-Analysis)

A systematic review and meta-analysis of randomized trials showed that magnesium supplementation significantly reduced both ventricular and atrial arrhythmias after acute coronary syndrome compared with placebo. The effect was consistent across studies and provides strong evidence for magnesium’s role in preventing dangerous rhythm disturbances in high-risk heart patients.

Salaminia, S., et al. “Evaluating the Effect of Magnesium Supplementation and Cardiac Arrhythmias after Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.” BMC Cardiovascular Disorders, vol. 18, no. 1, 28 June 2018, p. 129. https://doi.org/10.1186/s12872-018-0861-1 (full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC6025730/).

Postoperative Atrial Fibrillation After Cardiac Surgery

Multiple meta-analyses of randomized controlled trials have shown that magnesium supplementation (intravenous or oral) significantly reduces the risk of new-onset atrial fibrillation following heart surgery. One recent large review confirmed magnesium lowers the incidence of postoperative Atrial fibrillation without increasing adverse events. This benefit is now widely recognized in cardiac surgery protocols.

Premature Ventricular and Atrial Contractions (PVCs and PACs)

Randomized trials have shown that oral magnesium supplementation can reduce the frequency and symptoms of premature cardiac contractions in patients without coronary artery disease. One well-designed study demonstrated meaningful improvement in both premature ventricular contractions and supraventricular ectopy with magnesium therapy. In my practice, patients with bothersome PVCs often see dramatic relief once magnesium levels are optimized.

Torsades de Pointes and Drug-Induced Arrhythmias

Intravenous magnesium is the standard, evidence-based treatment for torsades de pointes (a dangerous polymorphic ventricular tachycardia often triggered by QT-prolonging drugs). Magnesium rapidly suppresses early after-depolarizations and restores normal rhythm even when serum levels appear only mildly low.

Important Point: Serum magnesium levels are a poor indicator of total body stores. Red blood cell magnesium or ionized magnesium testing is far more accurate. Most patients with arrhythmias have low intracellular magnesium even if the basic blood test is “normal.”

References

Salaminia, S., et al. “Evaluating the Effect of Magnesium Supplementation and Cardiac Arrhythmias after Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.” BMC Cardiovascular Disorders, vol. 18, no. 1, 28 June 2018, p. 129. https://doi.org/10.1186/s12872-018-0861-1

DiNicolantonio, James J., et al. “Magnesium for the Prevention and Treatment of Cardiovascular Disease.” Open Heart, vol. 5, no. 2, 2018, e000775. https://doi.org/10.1136/openhrt-2018-000775Negru, A. G., et al. “The Role of Hypomagnesemia in Cardiac Arrhythmias.” Biomedicines, vol. 10, no. 10, 2022, p. 2356. https://doi.org/10.3390/biomedicines10102356

Baker, William L., et al. “Treating Arrhythmias with Adjunctive Magnesium: Identifying Future Research Directions.” European Heart Journal – Cardiovascular Pharmacotherapy, vol. 3, no. 2, 2017, pp. 108–117. https://doi.org/10.1093/ehjcvp/pvw028

Conclusion: Magnesium addresses the core problems of heart disease: inflammation, oxidative stress, mitochondrial dysfunction, endothelial impairment, and disordered lipid metabolism. It is safe, inexpensive, and available without a prescription.

Magnesium addresses the core electrical and metabolic problems that cause heart rhythm disorders. It is safe, inexpensive, and available without prescription. Dietary sources include leafy greens, nuts, seeds, and dark chocolate, but most patients with arrhythmias benefit from targeted supplementation (typically 300–400 mg elemental magnesium daily, using well-absorbed forms such as glycinate, taurate, or citrate).

Patients often ask me, “Why doesn’t my cardiologist talk about magnesium?” The answer is simple: it is not a patented pharmaceutical, so it receives far less attention than expensive drugs. Yet the medical literature is clear. Correcting magnesium deficiency is one of the most powerful, evidence-based steps you can take for preventing and reversing atherosclerotic plaque.

Disclaimer and Practical Advice

This information is for educational purposes and is not medical advice. Always consult your physician before starting any supplement program, especially if you have kidney disease or are on medications. Magnesium can interact with certain drugs, and excessive intake may cause loose stools. Work with a knowledgeable clinician who can monitor your levels and tailor therapy to your individual needs. Always consult your physician before starting any supplement program, especially if you have kidney disease or are on medications. Magnesium can interact with certain drugs, and excessive intake may cause loose stools. Work with a knowledgeable clinician who can monitor your levels and tailor therapy to your individual needs.Patients often ask me, “Why doesn’t my cardiologist talk about magnesium?” The answer is simple: it is not a patented pharmaceutical, so it receives far less attention than expensive drugs. Yet the medical literature is clear. Correcting magnesium deficiency is one of the most powerful, evidence-based steps you can take for heart rhythm health.

References
Veronese, Nicola, et al. “Effect of Magnesium Supplementation on Inflammatory Parameters: A Meta-Analysis of Randomized Controlled Trials.” Nutrients, vol. 14, no. 3, 2022, p. 679. https://doi.org/10.3390/nu14030679

Liu, Man, and Samuel C. Dudley Jr. “Magnesium, Oxidative Stress, Inflammation, and Cardiovascular Disease.” Antioxidants, vol. 9, no. 10, 2020, p. 907. https://doi.org/10.3390/antiox9100907

Shechter, Michael, et al. “Oral Magnesium Therapy Improves Endothelial Function in Patients With Coronary Artery Disease.” Circulation, vol. 102, no. 19, 2000, pp. 2353–58. https://doi.org/10.1161/01.cir.102.19.2353

DiNicolantonio, James J., et al. “Magnesium for the Prevention and Treatment of Cardiovascular Disease.” Open Heart, vol. 5, no. 2, 2018, e000775. https://doi.org/10.1136/openhrt-2018-000775

Talari, Hamid Reza, et al. “Effects of Magnesium Supplementation on Carotid Intima–Media Thickness and Metabolic Profiles in Diabetic Haemodialysis Patients: A Randomised, Double-Blind, Placebo-Controlled Trial.” British Journal of Nutrition, vol. 121, no. 7, 2019, pp. 809–817.

Articles with Related Interest:

Feel free to share this article with your doctor. Knowledge is power.

Jeffrey Dach MD

Published on June 1st, 2026 by Jeffrey Dach MD